Author

S. Q. Tsai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Barzel· 1 shared A. D. Nahmad· 1 shared A. Koch· 1 shared A. Liss· 1 shared A. Matsui· 1 shared A. Stern· 1 shared B. E. Russell· 1 shared C. F.-d. Castillo· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Barzel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Virus-free CRISPR knock-in of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells

K. Shankar, I. Zingler-Hoslet, L. Shi, V. Katta, B. E. Russell, S. Q. Tsai, C. M. Capitini, K. Saha

This study uses CRISPR to disrupt an inhibitory receptor in NK cells and insert a GD2-targeting CAR, creating potent NK cells against GD2+ melanoma.

bioRxiv · Feb 14, 2024 · PreprintBioengineering

IFNA pathway drives the more aggressive phenotype of KRASG12D-mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation

D. G. Duda, K. Inoue, D. H. Schanne, A. Matsui, P. Lei, S. Klein, S. Aoki, H. Taniguchi, H. Kikuchi, J. Chen, Z. Liu, S. Q. Tsai, T. C. Schmidt, M. Iwasaki, G. Geidel, , N. Bardeesy

The paper shows that the IFNA pathway promotes aggressive KRASG12D-mutant pancreatic ductal adenocarcinomas through IFNAR1/STAT3 activation and identifies IFNAR1 inhibition as a potential therapeutic strategy.

bioRxiv · Jun 29, 2022 · PreprintCancer Biology

In vivo engineered B cells retain memory and secrete high titers of anti-HIV antibodies in mice

A. D. Nahmad, C. R. Lazzarotto, N. Zelikson, T. Kustin, M. Tenuta, D. Huang, I. Reuveni, M. Horovitz-Fried, I. Dotan, R. Rosin-Arbesfeld, D. Nemazee, J. E. Voss, A. Stern, S. Q. Tsai, A. Barzel

bioRxiv · Apr 8, 2021Immunology